Figure 4

Bioluminescent imaging and histopathological findings. Bioluminescent imaging in five representative mice from each group (A, control; B, 18 mg/kg; C, 27 mg/kg). Bioluminescent imaging showed a tendency for decreases in the extension of metastasis in raloxifene-treated groups as compared to the control group. D. The implanted mammary carcinomas proved to be moderately differentiated adenocarcinoma. ×200. E. p53 immunohistochemistry of mammary carcinoma induced by BJMC3879 cell inoculation. Note the nuclear staining for abnormal p53 protein, indicating that these cells carry mutant p53. × 400. F. Metastasis to lymph node in control mice (×40, inset). Metastatic carcinoma cells were filled with sinusoidal space (× 400). G. A lymph node from a mouse given 27 mg/kg raloxifene (× 40, inset). Metastatic carcinoma cells were filled with subcapsular sinus and sinusoidal space (× 400). H. Metastatic foci in the lung of a control mouse. Many metastatic foci and small to large nodules were seen. × 40. I. Metastatic foci in the lungs of mice given 27 mg/kg raloxifene. Metastatic lung foci were much smaller in the 27 mg/kg group than in the control group. × 40. J and K. Uterine endometrium was histopathologically similar between control and raloxifene-treated mice. × 100. D and F-K, H&E stain; B, p53 immunohistochemistry.